👋 Hey, let’s get into it. James Bond had a license to kill. Moderna now has one too...sort of.

The company introduced its first in vivo CAR-T program last week, internally dubbed "007," with plans to turn a patient's own immune cells into cancer-fighting-style assassins for autoimmune disease. Instead of manufacturing CAR-T cells outside the body, Moderna wants to send the instructions directly into patients using the same mRNA playbook that made it famous.

If it works, CAR-T could become dramatically easier to manufacture, distribute, and scale. The name may be a joke, but the opportunity definitely isn't.

💰 Merck KGaA Buys Bio-Techne for $11.3 Billion
Merck KGaA is doubling down on life sciences with an $11.3 billion acquisition of Bio-Techne, marking its biggest deal since buying Sigma-Aldrich in 2015. The acquisition adds a powerhouse portfolio of proteins, antibodies, analytical instruments, multi-omics tools, and bioprocessing technologies that scientists rely on every day. Merck expects roughly €140 million in annual cost synergies within three years, while strengthening its position across next-generation biology and advanced therapeutics. If biotech is entering another investment cycle, Merck clearly wants to be selling everyone the picks and shovels.

🤝 Ipsen Acquires Kartos in $1.7 Billion Bet on Phase 3 Myelofibrosis Drug
Ipsen is paying $450 million upfront, with up to $1.3 billion in milestones, to acquire Kartos Therapeutics and its Phase 3 MDM2 inhibitor navtemadlin. The drug is designed to restore p53 activity in myelofibrosis patients who no longer respond well to Jakafi, the current standard of care. Rather than replacing Jakafi outright, Ipsen is betting many patients will eventually need something more effective. With late-stage data already in hand, the company just bought itself a serious shot at becoming a major player in hematologic oncology.

✅ FDA Picks Eli Lilly, Regeneron and Five Others for Manufacturing Fast Track
The FDA just unveiled the first picks for its new PreCheck pilot program, selecting Eli Lilly, Regeneron, Fujifilm Biotechnologies, Cellares, Kyowa Kirin, Kriya Therapeutics and Amneal as its first participants. Instead of waiting until factories are finished, regulators will begin reviewing facilities while they're still being built, potentially cutting as much as 14 months off approval timelines. It's another signal that domestic manufacturing has become a strategic priority and that the FDA is looking for ways to accelerate access without lowering standards.

👑 Zymeworks Acquires Theravance for $929 Million and a Portfolio of Royalty Streams
Only months after slashing its R&D organization, Theravance has found a buyer. Zymeworks will pay $929 million for the company, adding COPD therapy Yupelri, multiple royalty agreements, milestone payments, and billions in Irish tax attributes. Rather than making a pure pipeline acquisition, Zymeworks is buying predictable cash flow to support its oncology ambitions. Sometimes the most valuable biotech assets aren't experimental drugs. They're the checks already coming in.

💪 Epicrispr Reports First Ever Clinical Muscle Growth with Epigenetic Gene Silencing
Epicrispr reported the first clinical evidence that epigenetic editing can increase lean muscle in patients with facioscapulohumeral muscular dystrophy, a devastating disease with no approved treatments. Three patients receiving a single infusion of EPI-321 gained an average of roughly 0.8 pounds of lean muscle after six months by silencing the disease-driving DUX4 gene. It's an early study involving only a handful of patients, but demonstrating measurable muscle growth from gene silencing represents an encouraging proof of concept for an entirely new therapeutic approach.

☎️ AI-Powered Business Calling Starting at $12/User
Easily manage users, intelligently monitor business interactions, and improve productivity with AI-powered business communications. Learn more

🏭 Sandoz Moves Generic GLP-1 Closer to the U.S. Market
The FDA accepted Sandoz's applications for generic tirzepatide, the active ingredient in Mounjaro and Zepbound, potentially setting up one of the first U.S. competitors to Lilly's blockbuster GLP-1 franchise.

🙌 Gilead Expands Trodelvy into First-Line Triple-Negative Breast Cancer
The FDA broadened Trodelvy's label, allowing use across first-line metastatic TNBC regardless of PD-L1 status and intensifying the TROP2 ADC rivalry.

🦴 AstraZeneca Shares Phase 3 Data Behind Potential $5 Billion Bone Disease Drug
Efzimfotase alfa delivered positive Phase 3 results in hypophosphatasia, strengthening AstraZeneca's case for a blockbuster successor to Strensiq.

👁️ Viridian Wins FDA Approval for Lumvoa in Thyroid Eye Disease
Lumvoa becomes the first IGF-1R therapy approved for both active and chronic thyroid eye disease, giving Tepezza its first real competitor.

⏳ Pfizer Scores First Ibrance Label Expansion in Seven Years
The FDA approved Ibrance for HR-positive, HER2-positive metastatic breast cancer, extending its reach beyond HER2-negative disease.

🤩 Revolution Medicines Posts 82% Response Rate in Pancreatic Cancer
Revolution’s second RAS inhibitor, Zoldonrasib, paired with chemotherapy achieved an 82% response rate in KRAS G12D pancreatic cancer patients in an early-stage study.

For much of the past year, rare disease biotech CEOs felt like they were taking the same exam only to discover the grading rubric had changed overnight.

Now, the FDA appears to be changing course again.

Over the past two weeks, the agency surprised the industry by reversing earlier positions on gene therapies from uniQure and REGENXBIO, signaling that external controls, natural history studies and real-world evidence may once again play a meaningful role in supporting regulatory approvals for rare diseases.

That matters because randomized placebo-controlled trials simply aren't practical for many ultra-rare disorders. Recruiting enough patients can take years, and asking families to enroll in placebo arms becomes increasingly difficult when no effective therapies exist.

The shift could immediately benefit several companies already approaching the regulatory finish line. Capricor Therapeutics, awaiting an FDA decision on its Duchenne muscular dystrophy cell therapy in August, previously received a rejection partly because of concerns over external control data. Meanwhile, Skyhawk Therapeutics has generated encouraging Huntington's disease results using natural history comparisons, while Biohaven continues pushing for approval of its spinocerebellar ataxia therapy after a similar setback last year. Stoke Therapeutics has also discussed accelerated pathways using long-term external control data alongside its ongoing Phase 3 trial.

The broader message extends well beyond these four companies. Rather than insisting every rare disease program fit the traditional Phase 3 playbook, the FDA appears increasingly willing to evaluate evidence in the context of diseases where large, perfectly controlled trials may never be feasible.

For rare disease developers, that's more than a regulatory nuance. It could shave years off development timelines, reduce trial costs and, most importantly, get treatments to patients with few or no therapeutic options much sooner.

Sometimes the biggest breakthrough isn't a new drug. It's changing the rules that determine how one gets approved.

Read the full story 📖

That's how much Bayer's stock surged after the U.S. Supreme Court overturned a $1.25 million Roundup verdict, delivering the company's biggest one-day gain in 23 years. The ruling significantly weakens thousands of remaining state-law failure-to-warn lawsuits stemming from Bayer's 2018 acquisition of Monsanto, giving investors renewed confidence that one of pharma's most expensive legal battles may finally be turning a corner.

Here’s what biotech Redditors are talking about:

🏃 Is Thermo Fisher Worth the Interview Marathon?
One Reddit thread struck a nerve after a job seeker shared they'd reached four final-round interviews at Thermo Fisher in a month, only to be rejected each time while watching the roles get reposted days later. The overwhelming advice? Stop applying. The bigger surprise came when the OP said they believed Thermo had great culture because...the interviewers told them so.🤨 Reddit quickly responded with the equivalent of, "Of course they did." Asking an interviewer if their company has good culture is a bit like asking a restaurant if the food is good. You're probably not getting an unbiased review.

🤔 Stay for the Promotion or Jump Ship?
Another discussion asked whether it's worth sticking around at a company like Genentech long enough to earn a promotion. The consensus landed somewhere in the middle. Early in your career, spending several years at a respected company can strengthen your résumé, but only if you're actually progressing. If a promotion doesn't seem realistic after a couple of years, many argued it's perfectly reasonable to look elsewhere, especially if the next role comes with a bigger title instead of another lateral move.

🤖 Boehringer Bets on Immunai's AI Platform
Boehringer Ingelheim signed a discovery deal worth up to $15 million with Immunai to identify new T-cell targets for cancer and autoimmune diseases, notching Immunai’s third big pharma deal this year.

☁️ ICON Picks Microsoft as Its AI Partner
ICON selected Microsoft to power AI-enabled clinical trials, expanding its Orbis platform with Copilot, Azure and Fabric across the organization.

🌍 WHO Launches Ebola Therapeutics Trial
The WHO will evaluate Gilead's remdesivir and Mapp Biopharmaceutical's MBP134 during the latest Bundibugyo Ebola outbreak in the Democratic Republic of the Congo.

⚖️ Sanofi Faces EU Antitrust Investigation
European regulators formally opened an antitrust investigation into Sanofi over allegations it unfairly disparaged a competing flu vaccine in Germany and France.

🦣 Colossal Biosciences Wants to Preserve Every Endangered Species Before It's Too Late
Colossal Biosciences is best known for its ambitious de-extinction projects involving woolly mammoths and dire wolves, but its newest partnership may have an even bigger long-term impact. Working with the U.S. Fish and Wildlife Service, the company plans to collect, sequence and cryopreserve genetic material from more than 2,100 endangered species across the United States. The resulting biobank could support future conservation efforts, strengthen vulnerable populations through gene editing and preserve a genomic backup should any species disappear entirely. Whatever you think about de-extinction, building the world's largest endangered species genetic library is undeniably ambitious.

🫈 June 30, 1860: The Debate That Changed Biology Forever
Seven months after Charles Darwin published On the Origin of Species, one of science's most famous public debates unfolded inside the Oxford University Museum. With Darwin absent due to illness, biologist Thomas Henry Huxley defended evolution against Bishop Samuel Wilberforce, whose sarcastic remarks about Huxley's "ape ancestry" produced one of history's most memorable scientific comebacks. Whether every quote is perfectly accurate has been debated ever since, but the event marked a turning point. Scientific evidence had stepped onto the public stage, and it wasn't backing down. More than 165 years later, biology is still shaped by that willingness to challenge established thinking.

If there's one company that consistently steals biotech's spotlight, it's probably Colossal Biosciences. When your business model includes woolly mammoths, dire wolves, CRISPR, George Church and somehow Tony Robbins, you're operating in a category of your own.

We’re still convinced that if someone announced a universal cure for cancer on the same day Colossal unveiled a living T. rex...there would be at least a few newsrooms debating which story deserved the top headline.

That’s all for today. See you Thursday for the next issue. 👋

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead

BioNucleus Briefing lands in the inboxes of 1,100+ scientists, founders, investors, operators, and industry decision-makers twice a week.

If you'd like to sponsor a future issue, just hit reply and let's talk.